AnaptysBio logo

AnaptysBioNASDAQ: ANAB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 January 2017

Next earnings report:

11 March 2025

Last dividends:

N/A

Next dividends:

N/A
$627.14 M
-48%vs. 3y high
69%vs. sector
-vs. 3y high
-vs. sector
-93%vs. 3y high
88%vs. sector
-94%vs. 3y high
80%vs. sector

Price

after hours | Thu, 21 Nov 2024 00:00:12 GMT
$20.61+$0.53(+2.64%)

Dividend

No data over the past 3 years
$30.02 M$10.09 M
$30.02 M-$32.85 M

Analysts recommendations

Institutional Ownership

ANAB Latest News

AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock?
zacks.com08 November 2024 Sentiment: POSITIVE

AnaptysBio (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
globenewswire.com05 November 2024 Sentiment: POSITIVE

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update.

Anaptys Announces Participation in September Investor Conferences
globenewswire.com29 August 2024 Sentiment: POSITIVE

SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:

Why AnaptysBio Was Such a Healthy Stock This Week
fool.com23 August 2024 Sentiment: POSITIVE

The biotech saw some action thanks in no small part to a new analyst note. This reiterated an existing buy recommendation at a relatively high target price.

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point
seekingalpha.com15 August 2024 Sentiment: POSITIVE

AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expected in Q1 of 2025.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates
zacks.com05 August 2024 Sentiment: NEGATIVE

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $1.50 per share a year ago.

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
globenewswire.com05 August 2024 Sentiment: POSITIVE

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.

AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
zacks.com29 July 2024 Sentiment: NEGATIVE

AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst
benzinga.com22 July 2024 Sentiment: POSITIVE

HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.

AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
Zacks Investment Research01 May 2024 Sentiment: POSITIVE

AnaptysBio (ANAB) experienced a surge in stock price during the last trading session with higher than usual trading volume. Recent changes in earnings estimates indicate that the stock may continue to show strength in the future.

  • 1(current)

What type of business is AnaptysBio?

AnaptysBio, Inc. is a company that specializes in the development of immunological therapeutic drugs. AnaptysBio has a lineup of programs including Etokimab, ANB019, ANB030, and ANB032, which are designed to modulate therapeutic targets genetically linked to inflammatory diseases in humans. Previously known as Anaptys Biosciences, Inc., the company changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.

What sector is AnaptysBio in?

AnaptysBio is in the Healthcare sector

What industry is AnaptysBio in?

AnaptysBio is in the Biotechnology industry

What country is AnaptysBio from?

AnaptysBio is headquartered in United States

When did AnaptysBio go public?

AnaptysBio initial public offering (IPO) was on 26 January 2017

What is AnaptysBio website?

https://www.anaptysbio.com

Is AnaptysBio in the S&P 500?

No, AnaptysBio is not included in the S&P 500 index

Is AnaptysBio in the NASDAQ 100?

No, AnaptysBio is not included in the NASDAQ 100 index

Is AnaptysBio in the Dow Jones?

No, AnaptysBio is not included in the Dow Jones index

When was AnaptysBio the previous earnings report?

No data

When does AnaptysBio earnings report?

The next expected earnings date for AnaptysBio is 11 March 2025